A systematic review and meta-analysis reveals a substantial global burden of advanced liver fibrosis and cirrhosis, with pooled prevalence rates of 3.3% (95% CI, 2.4%–4.2%) and 1.3% (95% CI, 0.9%–1.7%) in the general population, respectively, which have shown an increasing trend in recent years ( Zamani et al., 2025 ).
← all excerpts
Luteolin and its derivatives: modulation of epithelial-mesenchymal transition in fibrosis and cancer.
1
—
—